Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.

NCT01058343 is registered in ClinicalTrials.gov with Neovacs as lead sponsor.

NCT NCT01058343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01058343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.
Lead sponsor
Neovacs
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2010
Completion date
June 30, 2016
Enrollment
28 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus